Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01774344 · ClinicalTrials.gov registry record · Phase 3
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 573
- Enrollment target
NCT01774344 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 573 participants.
The verdict
NCT01774344, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 573 participants
- Enrollment target
Study Summary
The objective of this study was to evaluate efficacy and safety of regorafenib in patients with advanced liver cancer who had progressed after sorafenib treatment. Patients were treated with regorafenib or placebo using a 2:1 randomization scheme.
Interventions
- DRUG Placebo
- DRUG Regorafenib (Stivarga, BAY73-4506)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 573 participants |
| Start Date | 2013-05-14 |
| Est. Completion | 2019-07-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01774344
The ClinicalTrials.gov registry entry for NCT01774344 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 573 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01774344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01774344 about?
NCT01774344 is a clinical study titled "Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma". The objective of this study was to evaluate efficacy and safety of regorafenib in patients with advanced liver cancer who had progressed after sorafenib treatment. Patients were treated with regorafenib or placebo using a 2:1 randomization scheme.
What is the current status of trial NCT01774344?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 573 participants. The study started on 2013-05-14. Estimated completion is 2019-07-05.
What interventions are being tested in trial NCT01774344?
The interventions under investigation include: Placebo (DRUG), Regorafenib (Stivarga, BAY73-4506) (DRUG).
Who is sponsoring clinical trial NCT01774344?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.